Access Digital Health
CountriesSignalsInterventionsToolsAbout
Log in
← Interventions

Cholesterol lowering treatment for those with Chol > 6 mmol/L and total CVD risk < 30%

Cost-effectiveness — what published models estimate per unit of health impact
$/DALY
$168–447
WHO-CHOICE modeled
GiveWell
—
no GiveWell model
CE sources
2
Tier A · 1 studies
Source agreement
material
sources differ
Loading effectiveness evidence…
Cost-effectiveness

Estimates are sourced in their native units and shown for comparison, not as literal costs. Sources use different frameworks — see each card for what it represents and how it was derived.

Modeled benchmarks ($/DALY)Tier A · standardized benchmark
South-East Asia$168.00View source →
Eastern sub-Saharan Africa$447.00View source →

WHO-CHOICE estimates are modeled at 50% population coverage, compared against the null set (no intervention) under generalized cost-effectiveness analysis. View WHO-CHOICE methodology →

$/DALY sources differ by 2.7x - a material difference.

Modeled regional estimates — not realized delivery costs.

Published study estimates ($/DALY)Tier B · context only
DCP3 (2013 reference)$22000median · 1 study

Varied methods — not directly comparable.

Data completeness: not assessed (no country selected) · Evidence confidence: not assessed (no country selected)
Delivery readiness is country-specific. Select a country in the selector above to see its health-system context — workforce density, financing mix, service coverage.
The figures above are published benchmarks. To build an investment case for your own context — local unit costs, target population, coverage assumptions — model it directly. Select a country first to carry its context into the model.
Choose a country to model →
Looking for supply/market data for Cholesterol lowering treatment for those with Chol > 6 mmol/L and total CVD risk < 30%? Select a country above, then open its intelligence page.